These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 23908670)
1. Risk factors for short term thyroid dysfunction after hematopoietic stem cell transplantation in children. Jung YJ; Jeon YJ; Cho WK; Lee JW; Chung NG; Jung MH; Cho B; Suh BK Korean J Pediatr; 2013 Jul; 56(7):298-303. PubMed ID: 23908670 [TBL] [Abstract][Full Text] [Related]
2. Changes in thyroid function parameters 3 months after allogeneic and autologous hematopoietic stem cell transplantation in children. Lebbink CA; Bresters D; Tersteeg JPB; van den Bos C; Dierselhuis MP; Lentjes EGWM; Verrijn Stuart AA; Fiocco M; Tissing WJE; van Santen HM Eur J Endocrinol; 2023 Jun; 188(6):503-509. PubMed ID: 37232272 [TBL] [Abstract][Full Text] [Related]
3. Thyroid dysfunction in children with leukemia over the first year after hematopoietic stem cell transplantation. Lee YJ; Lee HY; Ahn MB; Kim SK; Cho WK; Lee JW; Chung NG; Cho B; Suh BK J Pediatr Endocrinol Metab; 2018 Nov; 31(11):1241-1247. PubMed ID: 30325734 [TBL] [Abstract][Full Text] [Related]
4. Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Medinger M; Zeiter D; Heim D; Halter J; Gerull S; Tichelli A; Passweg J; Nigro N Leuk Res; 2017 Jul; 58():43-47. PubMed ID: 28433882 [TBL] [Abstract][Full Text] [Related]
5. Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: Influence of age and sex is confirmed, while a role of chronic graft-versus-host disease in delayed puberty onset is revealed. Weinhard S; Wiedemann A; Leheup B; Dalle JH; Lebon Labich B; Pochon C Pediatr Transplant; 2020 Sep; 24(6):e13773. PubMed ID: 32701220 [TBL] [Abstract][Full Text] [Related]
6. Subclinical hypothyroidism in children and adolescents after hematopoietic stem cells transplantation without irradiation. Milenković T; Vujić D; Vuković R; Zečević Ž; Soldatović I; Mitrović K; Todorović S; Zdravković D Vojnosanit Pregl; 2014 Dec; 71(12):1123-7. PubMed ID: 25639000 [TBL] [Abstract][Full Text] [Related]
7. Long-term thyroid disorders in pediatric survivors of hematopoietic stem cell transplantation after chemotherapy-only conditioning. Cima LN; Martin SC; Lambrescu IM; Stejereanu L; Zaharia C; Colita A; Fica S J Pediatr Endocrinol Metab; 2018 Aug; 31(8):869-878. PubMed ID: 29935114 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation of selected endocrine complications in patients treated with auto- and allo-haematopoietic stem cell transplantation]. Niedzielska E; Wójcik D; Barg E; Pietras W; Sega-Pondel D; Doroszko A; Niedzielska M; Skarzyńska M; Chybicka A Med Wieku Rozwoj; 2008; 12(3):761-6. PubMed ID: 19305027 [TBL] [Abstract][Full Text] [Related]
9. Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation. Ataca Atilla P; Akkus E; Atilla E; Gokmen N; Civriz Bozdag S; Kurt Yuksel M; Toprak SK; Baskal N; Akan H; Demirer T; Topcuoglu P; Arslan O; Ilhan O; Ozcan M; Beksac M; Gurman G Clin Transplant; 2020 Oct; 34(10):e14049. PubMed ID: 32713042 [TBL] [Abstract][Full Text] [Related]
10. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Mielcarek M; Martin PJ; Leisenring W; Flowers ME; Maloney DG; Sandmaier BM; Maris MB; Storb R Blood; 2003 Jul; 102(2):756-62. PubMed ID: 12663454 [TBL] [Abstract][Full Text] [Related]
11. Primary ovarian dysfunction after hematopoietic stem cell transplantation during childhood: busulfan-based conditioning is a major concern. Cho WK; Lee JW; Chung NG; Jung MH; Cho B; Suh BK; Kim HK J Pediatr Endocrinol Metab; 2011; 24(11-12):1031-5. PubMed ID: 22308860 [TBL] [Abstract][Full Text] [Related]
12. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313 [TBL] [Abstract][Full Text] [Related]
13. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512 [TBL] [Abstract][Full Text] [Related]
14. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843 [TBL] [Abstract][Full Text] [Related]